Ionis Pharmaceuticals (IONS) Tops Q4 EPS by 45c ; Offers Guidance

Ionis Pharmaceuticals (NASDAQ: IONS) reported Q4 EPS of ($0.66), $0.45 better than the analyst estimate of ($1.11). Revenue for the quarter came in at $227 million versus the consensus estimate of $135.58 million.

GUIDANCE:

Ionis Pharmaceuticals sees FY2025 revenue of ~$600 million, versus the consensus of $677.1 million.

For earnings history and earnings-related data on Ionis Pharmaceuticals (IONS) click here.

You May Also Be Interested In

• IDT Corp. (IDT) Tops Q3 EPS by 2c; offer guidance
• SpaceX files for 555.56M share IPO at $135/sh
• RBC Capital on Veeva Systems (VEEV) Amid After Hours Selloff on Earnings: 'we are surprised to see shares trade down'